Article Details

TJ-CD4B Aims to Expand the Bispecific Antibody Portfolio as Phase 1 Trial Kicks Off

Retrieved on: 2021-04-27 16:09:21

Tags for this article:

Click the tags to see associated articles and topics

TJ-CD4B Aims to Expand the Bispecific Antibody Portfolio as Phase 1 Trial Kicks Off. View article details on hiswai:

Excerpt

“Monoclonal antibodies targeting 4-1BB alone have been ineffective as they cause generalized activation of immune system which also damages the ...

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up